person · Reporting owner
BIENAIME JEAN JACQUES
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ascendis Pharma A/SASND · Entity 1628 | Director | April 14, 2026 | September 28, 2026 |
| IMMUNIC, INC.VTL · Entity 6306 | Director | September 24, 2018 | September 24, 2018 |
| INCYTE CORPINCY · Entity 3182 | Director | June 08, 2026 | June 10, 2026 |
| Immunome Inc.IMNM · Entity 4219 | Director | June 10, 2026 | June 12, 2026 |
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ascendis Pharma A/S
Report date April 14, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $172.35 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2026-04-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-14 · Disposition to issuer · Disposed 9,160 · Balance 0 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $249.84 · Expires 2036-04-14 | Direct | 9,160 |
Reported balance
After 2026-04-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-14 · Grant · Acquired 9,160 · Balance 9,160 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.
F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer.
F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.
IMMUNIC, INC.
Report date September 24, 2018 · Filed September 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,500 |
Reported balance
After 2018-09-24 transaction · row 1
1 source rowRow 1 · 2018-09-24 · Sale · Disposed 26,619 · Balance 18,500 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.
INCYTE CORP
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,424 |
Reported balance
After 2026-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 24,424 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
| Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07 | Direct | 6,111 |
Reported balance
After 2026-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
Immunome Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.16 · Expires 2036-06-09 | Direct | 9,897 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 9,897 · Balance 9,897 F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
Keros Therapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,592 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Purchase · Acquired 1,000 · Balance 19,592 F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOMARIN PHARMACEUTICAL INC
Report date May 20, 2024 · Filed May 21, 2024
Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 473,792 |
Reported balance
After 2024-05-20 transaction · row 1
1 source rowRow 1 · 2024-05-20 · Tax withholding · Disposed 1,202 · Balance 473,792 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Jean-Jacques Bienaime Family Trust | 247,333 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 247,333 |
| Common StockSEC Table I · non-derivative | IndirectShares held as UTMA custodian for child 1 | 100 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 100 |
| Common StockSEC Table I · non-derivative | IndirectShares held as UTMA custodian for child 2 | 100 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 100 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2019 Filed May 10, 2019 00:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 4,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-010325 · doc1.xml · derivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 4,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 08, 2019 Filed May 10, 2019 00:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,000 | $82.16 | $328,624.80 |
DisclosureSEC source: 0001567619-19-010325 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,520 F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $81.855 to $82.69. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 08, 2019 Filed May 10, 2019 00:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 4,000 | $14.39 | $57,560.00 |
DisclosureSEC source: 0001567619-19-010325 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. Read SEC document |
| April 30, 2019 Filed May 10, 2019 00:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 309 | $68.78 | $21,253.64 |
DisclosureSEC source: 0001567619-19-010325 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,520 F1 · date: Represents shares acquired by the reporting person on April 30, 2019, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 20:47 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,472 | $0.00 Strike: $75.03 | $0.00 |
DisclosureSEC source: 0001209191-19-026425 · doc4.xml · derivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,472 Underlying: Common Stock · 12,472 shares Expires 2029-04-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 20:47 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026425 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,584 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| April 26, 2019 Filed May 1, 2019 00:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-009492 · doc1.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 3,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 26, 2019 Filed May 1, 2019 00:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 200 | $84.41 | $16,881.00 |
DisclosureSEC source: 0001567619-19-009492 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,211 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. Read SEC document |
| April 26, 2019 Filed May 1, 2019 00:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 800 | $83.59 | $66,870.00 |
DisclosureSEC source: 0001567619-19-009492 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,411 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $83.225 to $84.15. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 26, 2019 Filed May 1, 2019 00:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,000 | $82.44 | $164,889.40 |
DisclosureSEC source: 0001567619-19-009492 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,211 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $82.085 to $83.03. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 26, 2019 Filed May 1, 2019 00:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,000 | $14.39 | $43,170.00 |
DisclosureSEC source: 0001567619-19-009492 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 23:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001567619-19-008967 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,000 Underlying: Common Stock · 1,000 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 23:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,000 | $21.51 | $21,510.00 |
DisclosureSEC source: 0001567619-19-008967 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2019 Filed Apr 16, 2019 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 4,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-008806 · doc1.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 4,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This trade is made pursuant to a 10b5-1 plan executed on March 5, 2019. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 12, 2019 Filed Apr 16, 2019 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,000 | $89.12 | $356,480.00 |
DisclosureSEC source: 0001567619-19-008806 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,211 F1 · date: This trade is made pursuant to a 10b5-1 plan executed on March 5, 2019. Read SEC document |
| April 12, 2019 Filed Apr 16, 2019 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 4,000 | $14.39 | $57,560.00 |
DisclosureSEC source: 0001567619-19-008806 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This trade is made pursuant to a 10b5-1 plan executed on March 5, 2019. Read SEC document |
| April 11, 2019 Filed Apr 16, 2019 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-008806 · doc1.xml · derivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 1,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 11, 2019 Filed Apr 16, 2019 00:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,000 | $14.39 | $14,390.00 |
DisclosureSEC source: 0001567619-19-008806 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-008644 · doc1.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 3,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This trade is made pursuant to a 10b5-1 plan executed on November 15, 2018. F5 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 700 | $93.67 | $65,571.94 |
DisclosureSEC source: 0001567619-19-008644 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,211 F1 · date: This trade is made pursuant to a 10b5-1 plan executed on November 15, 2018. F4 · price: The price in column 4 is the weighted average price. The price actually received ranged from $93.46 to $93.76. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 100 | $92.39 | $9,238.50 |
DisclosureSEC source: 0001567619-19-008644 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,911 F1 · date: This trade is made pursuant to a 10b5-1 plan executed on November 15, 2018. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $92.37 to $92.40. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,200 | $91.27 | $200,787.18 |
DisclosureSEC source: 0001567619-19-008644 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,011 F1 · date: This trade is made pursuant to a 10b5-1 plan executed on November 15, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $90.98 to $91.67. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 22:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,000 | $14.39 | $43,170.00 |
DisclosureSEC source: 0001567619-19-008644 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This trade is made pursuant to a 10b5-1 plan executed on November 15, 2018. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 22:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-008641 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 3,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This trade is made pursuant to a 10b5-1 plan executed on November 15, 2018. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 22:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,000 | $93.37 | $280,113.60 |
DisclosureSEC source: 0001567619-19-008641 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,211 F1 · date: This trade is made pursuant to a 10b5-1 plan executed on November 15, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $92.96 to $93.85. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 22:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,000 | $14.39 | $43,170.00 |
DisclosureSEC source: 0001567619-19-008641 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This trade is made pursuant to a 10b5-1 plan executed on November 15, 2018. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 168 | $86.01 | $14,449.68 |
DisclosureSEC source: 0001209191-19-022490 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,064 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 22:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-007870 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 1,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 22:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,000 | $14.39 | $14,390.00 |
DisclosureSEC source: 0001567619-19-007870 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 23:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 4,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-007678 · doc1.xml · derivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 4,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 23:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,000 | $87.86 | $351,440.00 |
DisclosureSEC source: 0001567619-19-007678 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,211 F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 23:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 4,000 | $14.39 | $57,560.00 |
DisclosureSEC source: 0001567619-19-007678 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 23:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 13,127 | $88.05 | $1,155,832.35 |
DisclosureSEC source: 0001567619-19-007678 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,211 Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 21:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-007385 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 1,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 21:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,000 | $14.39 | $14,390.00 |
DisclosureSEC source: 0001567619-19-007385 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 4,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-007247 · doc1.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 4,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 87,080 | $0.00 Strike: $94.53 | $0.00 |
DisclosureSEC source: 0001567619-19-007247 · doc1.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,080 Underlying: Common Stock · 87,080 shares Expires 2029-03-14 F3 · date: Option grant vests 12/48th on March 15, 2020 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,000 | $94.40 | $377,600.00 |
DisclosureSEC source: 0001567619-19-007247 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,338 F2 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 4,000 | $14.39 | $57,560.00 |
DisclosureSEC source: 0001567619-19-007247 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on September 10, 2018. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 34,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-007247 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,338 F1 · price: Restricted stock units granted on March 15, 2019. Price not applicable. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 23:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 28,143 | $94.53 | $2,660,357.79 |
DisclosureSEC source: 0001567619-19-007247 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,558 Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 18:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-006844 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 3,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 18:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,000 | $93.42 | $280,253.40 |
DisclosureSEC source: 0001567619-19-006844 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,701 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $93.09 to $94.05. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 18:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,000 | $14.39 | $43,170.00 |
DisclosureSEC source: 0001567619-19-006844 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 00:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 4,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-006805 · doc1.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 4,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 00:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,000 | $91.44 | $365,770.40 |
DisclosureSEC source: 0001567619-19-006805 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,701 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $91.22 to $91.77. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 00:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 4,000 | $14.39 | $57,560.00 |
DisclosureSEC source: 0001567619-19-006805 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. Read SEC document |
| March 11, 2019 Filed Mar 14, 2019 00:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 5,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-006805 · doc1.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 5,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 11, 2019 Filed Mar 14, 2019 00:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,000 | $88.96 | $444,779.50 |
DisclosureSEC source: 0001567619-19-006805 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,701 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $88.70 to $89.11. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| March 11, 2019 Filed Mar 14, 2019 00:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 5,000 | $14.39 | $71,950.00 |
DisclosureSEC source: 0001567619-19-006805 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 15, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.